Publications & Abstracts

Peer-reviewed research papers and abstracts by Immune-Onc scientists and our collaborators:

Featured
Oral Presentation—IO-202, A Novel Anti-LILRB4 Antibody, with Azacitidine for Hypomethylating Agent-Naive Chronic Myelomonocytic Leukemia: Phase 1b Expansion Cohort Results

Mannis G, et al. 66th ASH Annual Meeting and Exposition, December 7-10, 2024.

Publication—Phase I dose escalation study of IO-108, an anti-LILRB2 antibody, in patients with advanced solid tumors

Taylor MH, Naing A, Powderly J, et al. Journal for ImmunoTherapy of Cancer. November 21, 2024

Poster presented—Targeting LILRB4 (ILT3) using IO-202 in patients with chronic myelomonocytic leukemia (CMML): interim efficacy, safety, and mechanism of action data from the Phase 1b expansion cohort

Aribi, A., et al. European Hematology Association 2024. June 13–16, 2024

A first-in-human phase 1 study of IO-202 (anti-LILRB4 mAb) in acute myeloid leukemia (AML) with monocytic differentiation and chronic myelomonocytic leukemia (CMML) patients

DiNardo, C., et al. European Hematology Association 2023. June 8–15, 2023

A Novel Bispecific LILRB4 x CD3 Antibody with Potent killing of Monocytic Acute Myeloid Leukemia Cells

Huang, T., et al. The American Association for Cancer Research (AACR) Annual Meeting 2023. April 14–19, 2023

First-In-Human Phase 1 Trial of IO-108, an Antagonist Antibody Targeting LILRB2 (ILT4) as Monotherapy and in Combination with Pembrolizumab in Advanced Solid Tumors: Dose Escalation Data

Matthew H. Taylor, M.D. et al. The American Association for Cancer Research (AACR) Annual Meeting 2023. April 14–19, 2023

A Phase 1 Trial of IO-202, An Antagonist Antibody Targeting Myeloid Checkpoint LILRB4 (ILT3), in Adult Patients with Advanced Relapsed or Refractory Solid Tumors

Aung Naing, MD, et al. Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting & Pre-Conference Programs, Boston. November 8–12, 2022

Antagonistic Antibodies Targeting LAIR1 Enhance T Lymphocyte Activation and Promote Inflammatory Phenotypes in Myeloid Cells

Sabharwal, S. et al. Society for Immunotherapy of Cancer (SITC) Tumor Immune Microenvironment Workshop 2022. April 21–22, 2022

A First-In-Human Phase 1 Trial of IO-108 as Monotherapy and in Combination with Pembrolizumab in Adult Patients with Advanced Relapsed or Refractory Solid Tumors

Powderly, J. M.D. et al. The American Association for Cancer Research (AACR) Annual Meeting 2022. April 8–13, 2022

IO-108, a Fully Human Therapeutic Antibody Blocking the Myeloid Checkpoint LILRB2/ILT4, Promotes Innate and Adaptive Anti-Cancer Immunity in Preclinical Studies

Ma J. et al. The American Association for Cancer Research (AACR) Annual Meeting 2022. April 8–13, 2022

LILRB3 supports acute myeloid leukemia development and regulates T-cell antitumor immune responses through the TRAF2–cFLIP–NF-κB signaling axis

Wu G. et al. 2021. Nature Cancer. 2(11):1170-1184.

Leukocyte immunoglobulin-like receptor subfamily B: therapeutic targets in cancer

Deng M. et al. 2021. Antibody Therapeutics. 4(1):16-33.

Antagonistic Antibodies Targeting LAIR1 Enhance T Lymphocyte Activation and Promote Inflammatory Phenotypes in Myeloid Cells

Huang T. et al. The Society for Immunotherapy of Cancer's (SITC) 36 Annual Meeting & Pre-Conference Programs, Washington D.C. November 10-14, 2021

IO-202, a first-in-class LILRB4 antagonist antibody, activates dendritic cells and inhibits solid tumor growth in preclinical studies.

Costa M. et al. The American Association for Cancer Research (AACR) Annual Meeting 2021, Virtual. April 10-15, 2021

Leukocyte immunoglobulin-like receptor subfamily B: therapeutic targets in cancer

Deng M. et al. Antibody Therapeutics. 2021; 4: 16-33.

A First-in-Human Phase 1 Study of the Anti-LILRB4 Antibody IO-202…

DiNardo C. et al. A First-in-Human (FIH) Phase 1 Study of the Anti-LILRB4 Antibody IO-202 in Relapsed/Refractory (R/R) Myelomonocytic and Monocytic Acute Myeloid Leukemia (AML) and R/R Chronic Myelomonocytic Leukemia (CMML). Blood. 2020; 136 (Supplement 1): 19–20.

Preclinical characterization of a novel therapeutic antibody targeting LILRB2

Costa M. et al. The Society for Immunotherapy of Cancer (SITC) 35th Anniversary Annual Meeting & Pre-Conference Programs (SITC 2020), Virtual. November 9-14, 2020.

LILRB4-targeting Antibody–Drug Conjugates for the Treatment of Acute Myeloid Leukemia

Anami Y. et al. 2020. Molecular Cancer Therapeutics. 19(11):2330-2339

Antagonist antibodies targeting LAIR1 promote inflammatory phenotype in myeloid cells and activate lymphocytes

Bonnans C. et al. Antagonist antibodies targeting LAIR1 promote inflammatory phenotype in myeloid cells and activate lymphocytes. Keystone Symposia on Myeloid Cells and Innate Immunity in Solid Tumors, Virtual. September 21-23, 2020.

Antagonistic anti-LILRB1 monoclonal antibody regulates antitumor functions of natural killer cells

Chen H. et al. 2020. Journal for ImmunoTherapy of Cancer .8(2):e000515.

Leukocyte immunoglobulin-like receptor B1 and B4 (LILRB1 and LILRB4)

Churchill H. Leukocyte immunoglobulin-like receptor B1 and B4 (LILRB1 and LILRB4): Highly sensitive and specific markers of acute myeloid leukemia with monocytic differentiation. Cytometry B Clin. Cytom. 2020; doi: 10.1002/cyto.b.21952.

LILRB4-targeting antibody-drug conjugates for the treatment of acute myeloid leukemia

Anami Y. et al. Mol. Cancer. Ther. 2020; 19: 2330–2339.

Antagonistic anti-LILRB1 monoclonal antibody regulates antitumor functions of natural killer cells

Chen H. et al. J. Immunother. Cancer. 2020; doi: 10.1136/jitc-2019-000515.

Phagocytosis checkpoints as new targets for cancer immunotherapy

Jiang W. et al. 2012. Nature Reviews Cancer. 19 (10), 568-586.

Disrupting LILRB4/APOE interaction by an efficacious humanized antibody reverses T-cell suppression and blocks AML development

Gui X. et al. Cancer Immunol. Res. 2019; 7: 1244-1257.

Targeting the immune inhibitory receptor LILRB4 to treat acute myeloid leukemia (AML)

Zhang C. et al. Keystone Symposia on Cancer Immunotherapy: Mechanistic Insights to Improve Clinical Benefit, Whistler, BC, Canada. March 10-14, 2019.

LILRB4 signalling in leukaemia cells mediates T cell suppression and tumour infiltration

Deng M. et al. Nature. 2018; 562: 605–609.

A Novel Anti-LILRB4 CAR-T Cell for the Treatment of Monocytic AML

John S. et al. 2018. Molecular Therapy 26(10):2487-2495.

Inhibitory leukocyte immunoglobulin-like receptors: Immune checkpoint proteins and tumor sustaining factors

Kang X. et al. 2016. Cell Cycle. 15(1):25-40.

The ITIM-containing receptor LAIR1 is essential for acute myeloid leukaemia development

Kang X. et al. 2015. Nature Cell Biology 17(5):665-677.